Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.

ABSTRACT:

Unlabelled

Antibodies and antibody-drug conjugates targeting the cell surface protein 6 transmembrane epithelial antigen of prostate 1 (STEAP1) are in early clinical development for the treatment of castration-resistant prostate cancer (PCa). In general, antigen expression directly affects the bioactivity of therapeutic antibodies, and the biologic regulation of STEAP1 is unusually complicated in PCa. Paradoxically, STEAP1 can be induced or repressed by the androgen receptor (AR) in different human PCa models, while also expressed in AR-null PCa. Consequently, there is an urgent need to translate diagnostic strategies to establish which regulatory mechanism predominates in patients to situate the appropriate therapy within standard of care therapies inhibiting AR.

Methods

To

SUBMITTER: Doran MG 

PROVIDER: S-EPMC4410715 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature